At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Ceralasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
In Brief
A Phase 2 clinical trial evaluating Ceralasertib for Advanced Solid Tumours. Completed, enrolled 54 participants across 18 sites in 3 countries.
Detailed Summary
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumours
CountriesFrance, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartDec 2020
Primary CompletionFeb 2025
TodayJul 2026
First PostedSep 25, 2020
Enrollment StartDec 1, 2020
Primary CompletionFeb 18, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 5.8 years ago
Interventions
Ceralasertibdrug
Tablets will be administered orally